Xyzagen Presents Spring Discovery’s Research on Disulfiram at ARVO 2023
Pittsboro, NC – April 28, 2023
Xyzagen, Inc., a pharmacokinetics consultancy and boutique CRO, unveiled new findings on the repurposing of disulfiram as a potential treatment for retinal diseases at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. The conference held April 23-27, in New Orleans, Louisiana.
The study, titled “SPR-397, 0.25% Ophthalmic Solution May Break the Inflammatory Cycle of Dry Eye Disease,” showcased findings on the novel applications of the FDA-approved drug being repurposed for Dry Eye Disease. This research holds promise for addressing this disease.
“The ARVO Annual Meeting is an excellent venue for sharing our client’s vision research advancements,”
said Christopher Crean, Founder and CEO of Xyzagen. “Our work on disulfiram underscores Xyzagen’s mission to support innovative strategies for repurposing known compounds to address complex diseases such as dry eye.”
Presentation Summary
About Xyzagen
Xyzagen augments a client’s pharmacology and pharmacokinetics drug development team. As a leading pharmacokinetics consultancy and contract research organization with wet lab and rodent vivarium facilities, Xyzagen is able to push model informed drug development into its First-in-Rat® and First-in-Mouse® discovery platforms as well as support late-stage clinical noncompartmental PK, PopPK, and Quantitative Medicine.
Our knowledge in pharmacology/pharmacogenomics and in vitro/in vivo pharmacokinetics allows the client to expand their core scientific team during the critical period of candidate selection up to the PreIND meeting and through clinical development and the preNDA meeting. We’re a boutique organization which allows for small clients and CROs to work directly with experts.
